Btk inhibitor for treating multiple sclerosis
Patent Information
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-05-03
- Publication Date
- 2026-03-11
AI Technical Summary
Current multiple sclerosis (MS) treatments often result in permanent disability progression, limited tolerability, and severe adverse events, with a need for more effective and tolerable therapies that address inflammatory components across various MS types and independently treat disability progression.
Administering a BTK inhibitor, Compound 1, in oral doses ranging from 200 mg to 1000 mg daily to treat MS, targeting both B cells and myeloid cells to reduce inflammation and slow disability progression.
The BTK inhibitor effectively treats MS by reducing inflammation and slowing disability progression, offering a safer and more tolerable option compared to existing therapies, with potential benefits in relapsing and progressive forms of the disease.
Smart Images
Figure US2024027812_14112024_PF_FP_ABST